Compare Stocks: ELOX, IKT, ACOG, and ANTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACOG Alpha Cognition	$8.52 +3.9%	$8.85	$4.50 ▼ $10.14	$185.85M	2.32	81,731 shs	226 shs
ANTX Anthem	$3.95 -5.5%	$4.81	$1.00 ▼ $7.19	$149.87M	-0.93	599,166 shs	7,178 shs
ELOX Eloxx Pharmaceuticals	$12.74	$14.91	$8.20 ▼ $23.40	$51.47M	-1918.69	25,252 shs	19,617 shs
IKT Inhibikase Therapeutics	$1.50 -4.5%	$2.02	$1.39 ▼ $2.61	$211.40M	0.94	1.06 million shs	16,465 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACOG Alpha Cognition	+4.02%	-6.98%	-6.78%	-1.61%	+47.07%
ANTX Anthem	+1.67%	-5.97%	-24.24%	-30.10%	+274.12%
ELOX Eloxx Pharmaceuticals	-1.39%	-2.90%	-17.33%	-28.06%	+105,189.26%
IKT Inhibikase Therapeutics	+5.74%	-3.40%	-21.75%	-35.06%	-1.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACOG Alpha Cognition	$8.52 +3.9%	$8.85	$4.50 ▼ $10.14	$185.85M	2.32	81,731 shs	226 shs
ANTX Anthem	$3.95 -5.5%	$4.81	$1.00 ▼ $7.19	$149.87M	-0.93	599,166 shs	7,178 shs
ELOX Eloxx Pharmaceuticals	$12.74	$14.91	$8.20 ▼ $23.40	$51.47M	-1918.69	25,252 shs	19,617 shs
IKT Inhibikase Therapeutics	$1.50 -4.5%	$2.02	$1.39 ▼ $2.61	$211.40M	0.94	1.06 million shs	16,465 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACOG Alpha Cognition	+4.02%	-6.98%	-6.78%	-1.61%	+47.07%
ANTX Anthem	+1.67%	-5.97%	-24.24%	-30.10%	+274.12%
ELOX Eloxx Pharmaceuticals	-1.39%	-2.90%	-17.33%	-28.06%	+105,189.26%
IKT Inhibikase Therapeutics	+5.74%	-3.40%	-21.75%	-35.06%	-1.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACOG Alpha Cognition	3.00	Buy	$18.00	111.24% Upside
ANTX Anthem	2.33	Hold	$9.00	127.85% Upside
ELOX Eloxx Pharmaceuticals	2.86	Moderate Buy	$37.33	193.04% Upside
IKT Inhibikase Therapeutics	2.90	Moderate Buy	$4.75	217.73% Upside

Current Analyst Ratings Breakdown

Latest ELOX, IKT, ACOG, and ANTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/28/2026	ELOX Eloxx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$43.00 ➝ $40.00
10/16/2026	ELOX Eloxx Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
10/15/2026	IKT Inhibikase Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	ELOX Eloxx Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight
10/13/2026	IKT Inhibikase Therapeutics	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target	Neutral	$1.50
10/13/2026	IKT Inhibikase Therapeutics	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Hold	$1.50
10/2/2026	ANTX Anthem	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/18/2026	ELOX Eloxx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target	Outperform	$32.00
9/18/2026	ELOX Eloxx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy	$32.00
8/24/2026	ELOX Eloxx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$43.00
8/20/2026	ACOG Alpha Cognition	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$21.00

(Data available from 11/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACOG Alpha Cognition	$10.22M	18.16	N/A	N/A	$2.88 per share	2.96
ANTX Anthem	N/A	N/A	N/A	N/A	$1.94 per share	N/A
ELOX Eloxx Pharmaceuticals	$6.36M	8.09	N/A	N/A	($85.17) per share	-0.15
IKT Inhibikase Therapeutics	$260K	802.36	N/A	N/A	$2.30 per share	0.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACOG Alpha Cognition	-$20.67M	-$1.10	N/A	N/A	N/A	-153.61%	-54.60%	-43.47%	11/11/2026 (Confirmed)
ANTX Anthem	-$35.17M	-$1.07	N/A	N/A	N/A	N/A	-53.52%	-48.63%	N/A
ELOX Eloxx Pharmaceuticals	-$5.99M	-$1.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-42.80%	-40.58%	N/A

Latest ELOX, IKT, ACOG, and ANTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ACOG Alpha Cognition	-$0.33	N/A	N/A	N/A	$7.04 million	N/A
8/13/2026	Q2 2026	ACOG Alpha Cognition	-$0.3921	-$0.40	-$0.0079	-$0.40	$4.38 million	$6.00 million
8/11/2026	Q2 2026	ANTX Anthem	N/A	-$0.18	N/A	-$0.18	N/A	N/A
8/11/2026	Q2 2026	ELOX Eloxx Pharmaceuticals	N/A	-$0.66	N/A	-$0.66	N/A	N/A
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	N/A
ANTX Anthem	N/A	N/A	N/A	N/A	N/A
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACOG Alpha Cognition	N/A	9.03	8.04
ANTX Anthem	N/A	14.32	14.32
ELOX Eloxx Pharmaceuticals	N/A	3.74	3.74
IKT Inhibikase Therapeutics	N/A	15.82	15.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACOG Alpha Cognition	N/A
ANTX Anthem	90.47%
ELOX Eloxx Pharmaceuticals	2.90%
IKT Inhibikase Therapeutics	3.81%

Insider Ownership

Company	Insider Ownership
ACOG Alpha Cognition	8.60%
ANTX Anthem	22.61%
ELOX Eloxx Pharmaceuticals	25.90%
IKT Inhibikase Therapeutics	7.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACOG Alpha Cognition	71	21.78 million	19.91 million	Optionable
ANTX Anthem	N/A	37.74 million	29.20 million	Optionable
ELOX Eloxx Pharmaceuticals	7	4.04 million	2.99 million	N/A
IKT Inhibikase Therapeutics	35	139.54 million	129.63 million	N/A

ELOX, IKT, ACOG, and ANTX Headlines

Recent News About These Companies

Inhibikase Therapeutics (NASDAQ:IKT) Stock Rating Lowered by Wall Street Zen

October 31, 2026 | marketbeat.com

Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During ...

October 27, 2026 | timesargus.comT

Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026

October 27, 2026 | globenewswire.com

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Stock Has Consensus Target Price of $4.75

October 23, 2026 | marketbeat.com

Inhibikase Therapeutics, Inc. Announces Board and Committee Changes, Effective October 19, 2026

October 21, 2026 | marketscreener.comM

Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors

October 20, 2026 | globenewswire.com

Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to "Hold" at Chardan Capital

October 14, 2026 | marketbeat.com

Chardan Initiates Inhibikase Therapeutics at Neutral With $1.50 Price Target

October 13, 2026 | finance.yahoo.com

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026

October 5, 2026 | biospace.comB

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT) and Nuvation Bio (NUVB)

September 18, 2026 | theglobeandmail.com

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

August 11, 2026 | globenewswire.com

FDA grants orphan drug designation to IKT-001 for PAH

July 30, 2026 | healio.comH

FDA grants orphan drug status to experimental PAH treatment

July 27, 2026 | pulmonaryhypertensionnews.comP

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

July 23, 2026 | globenewswire.com

Inhibikase sells $50M of common stock to RA Capital

July 14, 2026 | msn.com

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

July 14, 2026 | globenewswire.com

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 2, 2026 | globenewswire.com

Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)

June 29, 2026 | theglobeandmail.com

LifeSci Capital Keeps Their Buy Rating on Inhibikase Therapeutics (IKT)

May 17, 2026 | theglobeandmail.com

Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors

May 14, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX, IKT, ACOG, and ANTX Company Descriptions

Alpha Cognition NASDAQ:ACOG

$8.52 +0.32 (+3.90%)

As of 10:05 AM Eastern

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Anthem NASDAQ:ANTX

$3.95 -0.23 (-5.50%)

As of 10:04 AM Eastern

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Eloxx Pharmaceuticals NASDAQ:ELOX

$12.74 0.00 (0.00%)

As of 11/4/2026 04:00 PM Eastern

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

Inhibikase Therapeutics NASDAQ:IKT

$1.50 -0.07 (-4.47%)

As of 10:05 AM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELOX, IKT, ACOG, and ANTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELOX, IKT, ACOG, and ANTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELOX, IKT, ACOG, and ANTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX, IKT, ACOG, and ANTX Company Descriptions

Alpha Cognition NASDAQ:ACOG

Anthem NASDAQ:ANTX

Eloxx Pharmaceuticals NASDAQ:ELOX

Inhibikase Therapeutics NASDAQ:IKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELOX, IKT, ACOG, and ANTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELOX, IKT, ACOG, and ANTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELOX, IKT, ACOG, and ANTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX, IKT, ACOG, and ANTX Company Descriptions

Alpha Cognition NASDAQ:ACOG

Anthem NASDAQ:ANTX

Eloxx Pharmaceuticals NASDAQ:ELOX

Inhibikase Therapeutics NASDAQ:IKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools